🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT07279727
Starting soon Phase 1

Ultrasound-Guided Infraclvicular Block Using Dexmedetomidine Versus Nalbuphine as Adjuvants to Bupivacaine in Upper Limb Orthopedic Surgery

NCT07279727 · tracked via the Priya Life Science Egypt tracker
Phase
Phase 1
Started
2026-01-01
Last updated
2025-12-12

Condition(s) studied

Regional Anaesthesia

Investigational drug(s) / intervention(s)

Nalbuphine →Dexmedetomidine →

Nalbuphine: Nalbuphine will be added to .5% bupivacaine as an adjuvant in infraclavicular nerve block

Dexmedetomidine: Dexmedetomidine will be added to .5% bupivacaine as an adjuvant in infraclavicular nerve block

Study summary

this study is designed to evaluate and compare the efficacy of dexmedetomidine and nalbuphine as adjuvants to 0.5% bupivacaine in ultrasound-guided infraclavicular brachial plexus block for patients undergoing elective upper limb orthopedic surgeries on the duration of analgesia.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: Adults aged 18-65 years ASA I-II (American Society of Anesthesiologists physical status classification) Scheduled for elective upper limb orthopedic surgeries Able to provide informed consent to participate in the study Exclusion Criteria: Refusal to participate in the study Pregnancy Allergy to any study drug(s) Neurological disease (e.g., neuropathies, central nervous system disorders) Coagulopathy or active bleeding disorders Severe systemic diseases (e.g., uncontrolled cardiovascular, renal, or liver disease) Opioid abuse or history of substance use disorder

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Faculty of medicine Assiut University, Assiut, Asyut Asyut Governorate

More Assiut University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07279727 on ClinicalTrials.gov ↗ ← All trials in Egypt